ACOR
Acorda Therapeutics Inc
Acorda Therapeutics Inc
$ACOR reports Q4 and FY2022 financial results, meets INBRIJA guidance and expects decline in AMPYRA revenue in 2023
Acorda Therapeutics met its global financial guidance for 2022 with its full-year global INBRIJA net revenue of $30.9 million, although it saw its Q4 2022 INBRIJA U.S. net revenue drop by 13.1%. While AMPYRA net revenue for 2022 was $72.9 million, it is expected to decline due to generics entering the market in 2018. Acorda's CEO expects to increase the trajectory of INBRIJA, maintain the strength of the AMPYRA brand, and reduce operating expenses in 2023. The company anticipates adjusted OPEX of $93-$103 million and an ending cash balance of $43-$47 million for 2023, which includes the impact of new supply agreement with Catalent.
21d ago
$ACOR